FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer By Ogkologos - March 23, 2026 545 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FX-909-CLINPRO-1 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Durvalumab Modestly Improves Survival in Advanced Biliary Tract Cancer February 10, 2022 Teen Invents ‘Resilience Bra’ To Help Breast Cancer Patients With Post-Mastectomy... June 13, 2019 Gentle regular exercise could reduce the risk of liver cancer in... February 15, 2021 Νέα διαγνωστική μέθοδος για τον καρκίνο, με τη συμβολή της Microsoft August 5, 2019 Load more HOT NEWS Researchers Have Harnessed a Compound from a Common Plant Called Feverfew... New targeted treatment for early breast cancer could reduce risk of... Volunteering with Pride: Brett’s award-winning involvement with Cancer Research UK EMA Recommends Granting a Marketing Authorisation for Capivasertib
